457 related articles for article (PubMed ID: 8093257)
1. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
2. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
4. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
Korngold R
Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
[TBL] [Abstract][Full Text] [Related]
5. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
Abraham VS; Sachs DH; Sykes M
J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
[TBL] [Abstract][Full Text] [Related]
7. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
8. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
9. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
10. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia.
OKunewick JP; Kociban DL; Machen LL; Buffo MJ
Bone Marrow Transplant; 1991 Dec; 8(6):445-52. PubMed ID: 1686416
[TBL] [Abstract][Full Text] [Related]
11. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
12. Strain dependence of interleukin-2-induced graft-versus-host disease protection: evidence that interleukin-2 inhibits selected CD4 functions.
Sykes M; Harty MW; Pearson DA
J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):11-21. PubMed ID: 8110726
[TBL] [Abstract][Full Text] [Related]
13. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
Aizawa S; Kamisaku H; Sado T
Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
15. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
[TBL] [Abstract][Full Text] [Related]
16. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
17. Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.
de la Selle V; Miconnet I; Gilbert D; Bruley-Rosset M
Bone Marrow Transplant; 1995 Jul; 16(1):111-8. PubMed ID: 7581109
[TBL] [Abstract][Full Text] [Related]
18. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
20. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
